Diabetes: The Silent Epidemic1

Since the beginning of the COVID pandemic in 2020, diabetes-related deaths have risen by almost 17% compared to 2019. This increase was higher than any other cause of death by any disease and a trend in the wrong direction2.

Man wears a FreeStyle Libre 3 sensor to help manage his diabetes
Man wears a FreeStyle Libre 3 sensor to help manage his diabetes
Man wears a FreeStyle Libre 3 sensor to help manage his diabetes

Trend drivers and insights impacting you and your employees

1 in 10 Americans is living with diabetes3

$327 billion: Total cost of diagnosed diabetes in the United States in 20174

o   $237 billion in direct medical costs4

o   $90 billion in reduced productivity4

o   ~2.3X higher medical expenditures ($16,752 average PPPY) for people living with diabetes4

14 million lost days due to workplace diabetes-related absenteeism5

The cost of missed workdays (ranging from 1.0 to 4.2 days/employee) due to diabetes-related absenteeism is estimated at $3.3 billion5.

Diabetes disproportionately affects racial and ethnic minorities6

Among adults with employer-sponsored insurance, Black (13.4%), Hispanic (13.3%), and Asian (14.1%) enrollees were more likely to have diabetes than White (8.8%) enrollees6.

Bend the trend with continuous glucose monitoring (CGM) and MyFreeStyle program

A continuous glucose monitor is a small, wearable, sensor-based system that measures glucose day and night.

The MyFreeStyle program is a diabetes education and support program that will guide your employees for more than 6 months along their diabetes management journeys using the FreeStyle Libre systems. If they're commercially insured or cash paying, your employees may be eligible to receive a voucher for a free* CGM sensor when they sign up today!

The MyFreeStyle program delivers personalized benefits straight to your employees, including:

Helpful emails

Topics to help guide their diabetes journeys

Interactive
check-ins

Proven outcomes with the FreeStyle Libre portfolio

The use of CGM systems has been shown to improve diabetes outcomesƗǂ7-9. Results from clinical trials and real-world studies highlight the benefits of the FreeStyle Libre portfolio of CGM systems for people living with diabetesƗǂ7-9.

Improved well-being and decreased disease burden

·        95% of users reported having a better understanding of their glucose fluctuationsƗǂ9

·        92% of users found it easier to manage meal-time glucoseƗǂ9

·        77% of users reported fewer hypoglycemic events†‡9

Reductions in work absenteeism

·       58% reduction in work absenteeism among patients with T1D/T2D [18.5% to 7.7%; P<0.05]Ɨǂ§9

·       50% reduction in absenteeism among patients with T1D [5.8% to 2.9%; P<0.0001]Ɨǂ§8

Reductions in diabetes-related hospitalizations and events

·       66% reduction in diabetes-related hospital admissions in T1D/T2D [187 (13.7%) to 32 (4.7%) at 12 months; P<0.05]Ɨǂ||9

·       61% reduction in acute diabetes events in T2D on intensive insulin regimens [P<0.001]Ɨǂ¶7

Video testimonial from Dr. Eden Miller

Innovating for access and affordability

5 million users
worldwide10

1.6 million
users in the US10

Precision
manufacturing

Advancing health
equity through
partnerships11

Sustainable
sourcing11

The cost of other CGMs#10

 

Lower cost careƗǂ12

Diversity in
clinical trials11

Let's talk

Learn more about how Abbott and the FreeStyle Libre portfolio can help you and your employees bend the trend with CGM.

Abbott provides this information as a courtesy; it is subject to change and interpretation. The customer is ultimately responsible for determining the appropriate codes, coverage, and payment policies for individual patients. Abbott does not guarantee third party coverage or payment for our products or reimburse customers for claims that are denied by third party payors. Medicare coverage is available for FreeStyle Libre systems if their respective readers are used to review glucose data on some days every month. Medicare and other third party payor criteria apply.

The FreeStyle Libre 2 or 3 apps are only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the apps. Use of the apps may require registration with LibreView. 

The FreeStyle Libre 2 app and the FreeStyle Libre 2 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.

The FreeStyle Libre 3 app and the FreeStyle Libre 3 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see the Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.

* Eligible patients will receive one (1) FreeStyle Libre 2 sensor or (1) FreeStyle Libre 3 sensor for users with a compatible mobile phone operating system at $0 copay. The expiration date of the voucher is 60 days from the issue date. This program is available for patients with type 1, type 2, or gestational diabetes. Patients ages 18 and older are eligible to sign up and receive an offer for the (1) FreeStyle Libre 2 sensor or (1) FreeStyle Libre 3 sensor. Patients ages 4-17 are eligible to receive an offer for the (1) FreeStyle Libre 2 sensor or (1) FreeStyle Libre 3 sensor through their parent or guardian. This offer is void where prohibited by law. Abbott may modify or rescind this offer at any time without notice. The discounts are not available to beneficiaries of Kaiser Permanente, Medicare, Medicaid, or other federal or state healthcare programs, residents of Massachusetts, or US territories (other than Puerto Rico). The free (1) FreeStyle Libre 2 sensor or (1) FreeStyle Libre 3 sensor is provided as a sample and is limited to one sample per eligible person per product identification number. The FreeStyle Libre 2 sensor or FreeStyle Libre 3 sensor cannot be re-sold, traded nor submitted to any third-party payer for reimbursement and is not provided as any inducement for future purchases. The free sample card is not health insurance.
Ɨ Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore the study data is applicable to both products. 
ǂ Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 2 has the same features as FreeStyle Libre 14 day system with optional real-time glucose alarms. Therefore the study data is applicable to both products.
§ Represents percentage of patients reporting work absenteeism.
|| Represents percentage of people experiencing a diabetes-related hospital admission.

¶ Represents inpatient events or emergency outpatient events for hypoglycemia, hyperglycemia, diabetic ketoacidosis, or hyperosmolarity.
# Based on a comparison of list prices of the FreeStyle Libre personal CGM systems versus competitors’ CGM systems, assuming annual use of one receiver (or equivalent hardware) and quantity of transmitters and/or sensors according to use life.  The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.

References: 1. Broom, D. World Economic Forum (2020). https://www.weforum.org/agenda/2020/12/diabetes-silent-epidemic-world-health/ Accessed March 10, 2023. 2. Terhune, C. Reuters Investigates (2021). https://www.reuters.com/investigates/special-report/usa-diabetes-covid/  Accessed March 10, 2023.
3. Statistics About Diabetes (2019). https://diabetes.org/about-us/statistics/about-diabetes Accessed March 10, 2023. 4. Statistics About Diabetes (2022). https://diabetes.org/about-us/statistics/about-diabetes Accessed March 10, 2023. 5. American Diabetes Association. Diabetes Care (2018): https://doi.org/10.2337/dci18-0007 Accessed March 10, 2023. 6. “Health Disparities in Employer-Sponsored Insurance-Morgan Health-NORC” (2022). https://www.jpmorganchase.com/content/dam/jpmc/jpmorgan-chase-and-co/who-we-are/our-business/documents/jpmc-morgan-health-norc-report-ada.pdf  Accessed March 10, 2023. 7. Bergenstal, R. J Endocr Soc (2021): https://doi.org/10.1210/jendso/bvab013 8. Charleer S, et al. Diabetes Care (2020): https://doi.org/10.2337/dc19-1610 9. Fokkert, M. BMJ Open Diabetes Res Care (2019): https://doi.org/10.1136/bmjdrc-2019-000809 10. Data on file, Abbott Diabetes Care. 11. Abbott 2020 Sustainability Report. Accessed February 01, 2023. https://www.abbott.com/responsibility/sustainability.html 12. Frank JR, et al. Diabetes Technol Ther (2021): https://pubmed.ncbi.nlm.nih.gov/34546079/

ADC-70161 v2.0

Important Safety Information

FreeStyle Libre 14 day, FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety info.

The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.


No use of any Abbott trademark, trade name, or trade dress in this site may be made without prior written authorization of Abbott Laboratories, except to identify the product or services of the company.

This website and the information contained herein is intended for use by residents of the United States.

ADC-85718 v4.0